Acute and subacute invasive rhinosinusitis, sino-orbital infection, malignant otitis externa (MOE), and skull base osteomyelitis (SBO) represent a spectrum of presentations of cranial invasive fungal disease (IFD) \[[@CIT0001]--[@CIT0006]\]. Although each of these syndromes exhibits distinct clinical characteristics, they all may progress to involve similar anatomical structures including the skull base and cavernous sinus (CS) \[[@CIT0001], [@CIT0007]\]. IFD of the skull base or CS results in fatal vascular complications through inflammation or invasion of the adjacent internal carotid artery (ICA), leading to intraarterial thrombosis, aneurysm formation, or rupture \[[@CIT0010]\]. Invasive fungal carotiditis can have devastating consequences, including cerebral infarction, subarachnoid hemorrhage (SAH), and death. Despite these associations, vascular complications are infrequently considered or screened for in patients diagnosed with cranial IFD.

The incidence of IFD, including invasive aspergillosis (IA) and invasive mucormycosis (IM), continues to rise despite the development of novel antifungal agents for treatment and prophylaxis \[[@CIT0014]\]. Presentations of cranial IFD are usually nonspecific, making a prompt clinical and microbiological diagnosis challenging \[[@CIT0006], [@CIT0019]\]. With a growing population of immunosuppressed patients, and the high mortality rate of IFD, it is imperative to better understand the diverse clinical presentations of these invasive mycoses \[[@CIT0014], [@CIT0018], [@CIT0022]\].

We present 4 cases of invasive fungal carotiditis originating from the external auditory canal or paranasal sinuses, with eventual involvement of the ICA. To further characterize this clinical syndrome, we performed a systematic review of the literature and identified an additional 74 cases, suggesting that vascular and specifically carotid complications should be considered in patients presenting with cranial IFD.

METHODS {#s1}
=======

Case Series {#s2}
-----------

We conducted a retrospective study of all patients diagnosed with carotid involvement related to direct extension of IFD at Brigham and Women\'s Hospital from January 2003 to October 2018. Local databases were reviewed, and all patients diagnosed with proven or probable IFD per the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) \[[@CIT0023]\] were eligible for analysis. Patients were followed until January 2019 to ascertain outcomes. The study was approved by the Hospital\'s Office for Human Research Studies.

We collected data including demographics, medical comorbidities, clinical presentation, physical exam findings, radiographic findings, and diagnostic evaluation including laboratory values at presentation, (1→3)-β-D-glucan (BG), galactomannan (GM). Microbiological and histopathological findings were documented. Surgical intervention, antifungal therapy, disease complications, survival time from initial symptoms, and all-cause mortality were also recorded.

Systematic Review {#s3}
-----------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed \[[@CIT0024]\]. We searched the Medline/PubMed database from January 1958 to December 2018 for reports of *Aspergillus* or *Mucorales* infection with related occlusion, rupture, or aneurysm of the ICA. Cases before 1958 were omitted given the lack of antifungal therapy available before the approval of amphotericin B \[[@CIT0025], [@CIT0026]\]. The search terms combined text words, including *Aspergillus* OR aspergillosis, *Mucorales* OR mucor OR mucormycosis, AND stroke, carotid, aneurysm, sinus OR sinusitis, orbital apex, skull base, malignant otitis externa. The search strategy for PubMed is listed in [Supplementary Figure 1.](#sup1){ref-type="supplementary-material"} The searches were limited to human studies published in or translated to English. Additional studies were identified by reviewing references cited in relevant articles.

All cases of proven or probable IFD caused by *Aspergillus* or *Mucorales* species in patients aged ≥12 years with involvement of the sphenoid, ethmoid, or maxillary sinus, orbit, cavernous sinus, external auditory canal, clivus, temporal bone, or mastoid bone were considered \[[@CIT0024]\]. Cases with ICA occlusion, thrombosis, aneurysm formation, rupture, mycologic evidence of cranial infection (sino-orbital, sino-nasal, skull base, carotid), and radiographic evidence of contiguous infection were included. Cases with localized sinus disease were classified as sino-nasal, those with involvement of the sinus and orbit were classified as sino-orbital, and cases with involvement of the external auditory canal and temporal bone or skull base were classified at ototemporal. Patients with IFD and vascular complications secondary to hematogenous dissemination or surgical or traumatic inoculation were excluded. Cases with unclear origin of infection or unspecified treatment and outcome were excluded. Full-text articles were reviewed, and clinical information was extracted. Study quality was not assessed, as most manuscripts described single case reports.

Potential reports were screened for inclusion, first by title and abstract, and then assessed for eligibility and quality by full-text review. Data extraction was performed with a standardized data extraction tool, and a standardized protocol was followed. Patient characteristics extracted included age, gender, medical comorbidities, presenting symptoms, origin of infection, areas of involvement within the skull base, carotid involvement, empiric steroid therapy, infectious complications, fungal species diagnosed, antifungal therapy, surgical interventions, and death. For patients who received \>1 antifungal agent, the primary treatment regimen was determined to be the primary antifungal that was administered for \>1 month after diagnosis of cranial IFD.

We compared baseline characteristics using the Fisher exact test or Wilcoxon test according to the nature of the covariate. The primary outcome was median survival time from onset of symptoms. We generated survival curves using the Kaplan-Meier method. Statistical analysis was performed using JMP 14.0 (SAS Institute Inc, Cary, NC). The secondary outcome was to describe the presentation and clinical evolution of patients with invasive fungal carotiditis.

RESULTS {#s4}
=======

Case Series {#s5}
-----------

We identified 4 cases of invasive fungal carotiditis at our institution from 2003 to 2018. Characteristics of the cases are summarized in [Table 1](#T1){ref-type="table"}. IFD risk factors included diabetes mellitus (DM; n = 3), glucocorticoid use (n = 3), and hematologic malignancy (HM; n = 2). All cases were caused by *Aspergillus* species. Two cases were ototemporal, 1 was sino-orbital, and 1 was sino-nasal in origin. All patients were treated with antifungals with activity against *Aspergillus* species, with initial improvement in symptoms, imaging, or decrease in BG and GM serum values. All patients subsequently presented with occlusion or aneurysm of the ICA and cerebral infarcts. Relevant imaging findings for each patient are presented in [Figure 1](#F1){ref-type="fig"}. Three patients died within 1 year of diagnosis, whereas 1 patient remained alive at last follow-up after left superficial temporal artery to middle cerebral artery bypass and long-term antifungal therapy.

###### 

Cases of Invasive Fungal Carotiditis at Brigham and Women\'s Hospital, 2003--2018

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic               Patient 1                                                                                          Patient 2                                                                                                                        Patient 3                                                                                        Patient 4
  ---------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------
  Age, sex                     66 y, male                                                                                         79 y, male                                                                                                                       66 y, male                                                                                       77 y, female

  Comorbidities                Follicular NHL treated with fludarabine; paraneoplastic pemphigus requiring alemtuzumab and IVIG   CLL treated with rituximab and alemtuzumab in remission; type II DM                                                              Renal transplantation on tacrolimus, azathioprine; type II DM                                    End-stage renal disease; type II DM

  Presenting symptoms          Headache, CN III/VI palsy                                                                          Headache, left vision loss, periorbital pain, CN III palsy                                                                       Headache, facial pain, otalgia, left ear drainage                                                Headache, facial pain, otalgia, left ear drainage

  Diagnostic imaging           MRI/MRA with right parietal stroke, sphenoid and maxillary sinus disease, occlusion of right ICA   CT face with mass extending from left sphenoid sinus to orbit with dehiscence between the orbital apex and left sphenoid sinus   CT face with soft tissue density extending from left EAC to mastoid with narrowing of left ICA   CT face with opacification of left EAC and mastoid air cells with bony erosion of sphenoid sinus and narrowing of left ICA

  Peak serum BG and GM index   BG \>500 pg/mL^a^\                                                                                 BG 337 pg/mL\                                                                                                                    BG \>500 pg/mL\                                                                                  BG 329 pg/mL\
                               GM 0.26 index                                                                                      GM 0.31 index                                                                                                                    GM 1.23 index                                                                                    GM 1.51 index

  Origin                       Sino-nasal                                                                                         Sino-orbital                                                                                                                     Ototemporal                                                                                      Ototemporal

  Diagnostic criteria          Proven: biopsy with positive pathology and culture                                                 Proven: biopsy with positive pathology and IHC                                                                                   Probable: positive BG and GM, positive clinical criteria                                         Proven: biopsy with positive pathology and culture

  Histopathology               Right sphenoid sinus biopsy with hyphal forms                                                      Left orbital biopsy with hyphal forms and positive *Aspergillus* immuno-stain                                                    Left nasopharyngeal, skull base, sphenoid biopsies negative                                      Left mastoid and posterior ear canal with hyphal forms

  Microbiology                 Right sphenoid sinus culture with *Aspergillus fumigatus*                                          Left orbital cultures negative                                                                                                   Otic, skull base, clival, sinus cultures negative                                                Left posterior mastoid culture with *Aspergillus flavus*

  Antifungal treatment, d      Isavuconazole, 104; Voriconazole, 19                                                               Amphotericin, 16 Isavuconazole, 43                                                                                               Voriconazole, 294 Recrudescence → Voriconazole, 998                                              Isavuconazole, 37

  Surgical intervention        Sinus debridement                                                                                  Orbitotomy                                                                                                                       STA-MCA bypass                                                                                   Tympano-mastoidectomy, left ICA embolization

  ICA involvement              Right ICA occlusion                                                                                Left ICA occlusion                                                                                                               Left ICA occlusion                                                                               Left ICA ruptured aneurysm

  Complications                Cerebral infarct, SAH, basilar mycotic aneurysm                                                    Cerebral infarct, intracranial empyema                                                                                           Cerebral infarct                                                                                 Cerebral infarct, ruptured mycotic aneurysm

  Death                        Y                                                                                                  Y                                                                                                                                N                                                                                                Y

  Time to death,^b^ d          210                                                                                                120                                                                                                                              1823, alive as of 1/1/2019                                                                       150
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BG, (1→3)-β-D-glucan; CLL, chronic lymphocytic leukemia; CN, cranial nerve; CT, computed tomography; DM, diabetes mellitus; EAC, external auditory canal; GM, galactomannan; ICA, internal carotid artery; IHC, immunohistochemistry; IVIG, intravenous immunoglobulin; MCA, middle cerebral artery; MRI/MRA, magnetic resonance imaging/angiography; NHL, non-Hodgkin\'s lymphoma; SAH, subarachnoid hemorrhage; STA, superficial temporal artery.

^a^Attributed to intravenous immunoglobulin at the time.

^b^From symptom onset.

![A and B, Patient 1 developed invasive fungal carotiditis of sino-nasal origin. He received antifungal treatment and experienced clinical improvement. He was readmitted 4 months later with acute-onset headache and syncope and was found to have diffuse subarachnoid hemorrhage (A) and basilar summit mycotic aneurysm (B). C and D, Patient 2 presented with occlusion of the left internal carotid artery (ICA) (C) and invasive fungal carotiditis of sino-orbital origin (D). The patient was treated with isavuconazole and experienced clinical improvement. He was readmitted 2 months later with acute loss of consciousness and was found to have cerebral infarcts and cranial fossa empyema. E and F, Patient 3 developed invasive fungal carotiditis of ototemporal origin complicated by occlusion of the left ICA (E) and ipsilateral cerebral infarcts (F). The patient improved with voriconazole treatment and underwent superficial temporal artery to middle cerebral artery bypass. G and H, Patient 4 developed invasive fungal carotiditis of ototemporal origin. The patient was treated with isavuconazole and experienced clinical improvement. She was readmitted one month later with acute-onset epistaxis and was found to have ruptured left ICA mycotic aneurysm (G). Despite vessel sacrifice (H), she subsequently died.](ofz392f0001){#F1}

Systematic Review {#s6}
-----------------

### Demographics and Comorbidities {#s7}

We identified 74 additional cases of invasive fungal carotiditis between January 1958 and December 2018. This review focused on localized cranial IFD; cases of IFD secondary to hematogenous dissemination were excluded. Forty-one cases were caused by *Aspergillus* and 37 by *Mucorales* species. Patient demographics and comorbidities are presented in [Table 2](#T2){ref-type="table"}. Among cases, patients with IM were younger overall compared with patients with IA (IM median age, 47 years; IA median age, 70 years). The most common comorbidities were DM (58%), HM (12%), and chronic kidney disease (CKD; 10%). Few patients (4%) had undergone allogeneic hematopoietic cell transplantation (HCT). Sixteen patients (21%) had no apparent risk factors for cranial IFD that were identified. Fifty-one patients (65%) had 1 risk factor for IFD, and 11 (14%) had multiple risk factors. Diabetes was the most frequent individual risk factor for IFD (44%). Patients with cases due to IM were more likely to have DM as a primary risk factor (62% vs 27%; *P* = .003), and patients with cases due to IA were more likely to have no identifiable risk factors (32% vs 8%; *P* = .02).

###### 

Clinical Characteristics and Risk factors for Invasive Fungal Carotiditis

  Clinical Presentation                 *Aspergillus* sp. (n = 41)   *Mucorales* (n = 37)    Total (n = 78)          *P*
  ------------------------------------- ---------------------------- ----------------------- ----------------------- --------
  Demographics                                                                                                       
  Median age \[range, IQR\], y          70 \[15--83, 52--77\]        47 \[15--80, 35--61\]   60 \[15--83, 44--73\]   \<.001
  Male sex, No. (%)                     27 (66)                      21 (57)                 48 (62)                 .554
  Comorbidities, No. (%)^a^                                                                                          
   Diabetes mellitus                    16 (39)                      29 (78)                 45 (58)                 .001
   Hematologic malignancy               5 (12)                       4 (11)                  9 (12)                  .999
   Chronic kidney disease               3 (7)                        5 (13)                  8 (10)                  .598
   Autoimmune disease                   5 (12)                       2 (5)                   7 (9)                   .521
   Solid organ transplant^b^            5 (12)                       0                       5 (6)                   .071
   Other immunodeficiency^c^            1 (2)                        3 (8)                   4 (5)                   .539
   Hematopoietic cell transplantation   1 (2)                        2 (5)                   3 (4)                   .922
   Solid organ malignancy               1 (2)                        1 (3)                   2 (3)                   .999
   No comorbidities identified          12 (24)                      3 (8)                   15 (19)                 .034
  Presenting symptoms, No. (%)                                                                                       
   Vision change                        30 (73)                      27 (73)                 57 (73)                 .999
   Ptosis or cranial nerve palsy        27 (66)                      27 (73)                 54 (69)                 .665
   Headache                             21 (51)                      12 (32)                 33 (42)                 .147
   Facial or periorbital edema          9 (22)                       22 (59)                 31 (40)                 .001
   Facial or periorbital pain           15 (37)                      13 (35)                 28 (36)                 .999
   Nasal or sinus symptoms              2 (5)                        10 (27)                 12 (15)                 .015
   Retro-orbital pain                   5 (12)                       3 (8)                   8 (10)                  .831
   Epistaxis                            3 (7)                        4 (11)                  7 (9)                   .884
   Otalgia or otorrhea                  5 (12)                       1 (3)                   6 (8)                   .251
  Mode of extension, No. (%)                                                                                         
   Sino-nasal                           17 (41)                      15 (40)                 32 (41)                 .999
   Sino-orbital                         20 (49)                      22 (60)                 42 (54)                 .474
   Ototemporal                          4 (10)                       0                       4 (5)                   .142

Abbreviation: IQR, interquartile range.

^a^Of note, patients had multiple concomitant comorbidities; percent values will not add to 100. Twenty-one percent of patients had no risk factors for invasive fungal disease (IFD; 65% had 1 risk factor for IFD, and 14% had \>1 risk factor for IFD.

^b^On glucocorticoid therapy.

^c^Including hypogammaglobulinemia, pancytopenia, and glucocorticoid therapy.

### Clinical Features {#s8}

The most common presenting symptoms were changes in vision including diplopia or vision loss (IA 73%, IM 73%), cranial nerve palsy (IA 66%, IM 73%), headache (IA 51%, IM 32%), and facial or periorbital pain (IA 37%, IM 35%) ([Table 2](#T2){ref-type="table"}). Patients with mucormycosis frequently had periorbital edema or proptosis (59% vs 22%; *P* = .001). Other presenting symptoms included retro-orbital pain, otalgia or otorrhea, epistaxis, and rhinorrhea or sino-nasal symptoms.

### Disease Manifestations {#s9}

The close proximity of anatomical structures in the sinuses and skull base as well as limitations to radiologic diagnosis make the categorization of subtypes of cranial IFD challenging. In this review, cases were divided into sino-nasal, sino-orbital, and ototemporal modes of extension to the ICA. Cases of sino-nasal origin or sino-orbital origin most commonly progress from the paranasal sinuses to involve the cavernous sinus or via the sphenoid to invade the skull base. Cases of ototemoporal origin typically progress via the external auditory canal to involve the skull base via the temporal bone. Sino-nasal and sino-orbital modes of extension comprised 41% and 54% of cases, respectively. Only 4 patients developed invasive fungal carotiditis of ototemporal origin. Though almost all cases displayed involvement of the sinuses, only 14% of patients noted sino-nasal symptoms or rhinorrhea on presentation.

### Diagnosis and Microbiology {#s10}

Seventy-four cases were diagnosed as proven IFD by histopathology \[[@CIT0023]\]. Four cases caused by *Aspergillus* species were diagnosed as probable IFD by host factors, clinical features, and mycological evidence (positive GM n = 2, nonsterile sinus culture n = 2). Seventeen patients (41%) with invasive fungal carotiditis secondary to IA were empirically treated with systemic glucocorticoids before obtaining diagnosis, and 13 (32%) were diagnosed postmortem. Six patients (16%) with IM were treated with empiric glucocorticoids, and 8 (22%) were diagnosed postmortem. Patients were misdiagnosed with giant cell arteritis, optic neuritis, inflammatory pseudotumor (IgG4 disease), and other inflammatory syndromes.

Microbiologic data are presented in [Table 3](#T3){ref-type="table"}. The species isolated by culture included *Aspergillus fumigatus*, *Aspergillus flavus*, *Aspergillus niger*, *Rhizopus microsporus*, and *Rhizopus arrhizus*. In 8 cases, *Rhizopus* was identified by culture without identification to the species level performed. In 1 case, *Rhizomucor* was identified by culture, and in 1 case *Rhizomucor* was identified by histopathology. In 23 and 24 cases, respectively, *Aspergillus* and *Mucorales* were identified by histopathology alone.

###### 

Microbiology of Invasive Fungal Carotiditis

  Fungal Species                                 Frequency, No. (%)
  ---------------------------------------------- --------------------
  *Aspergillus* (n = 41)                         
   *Aspergillus fumigatus*                       14 (34)
   *Aspergillus flavus*                          1 (2.5)
   *Aspergillus niger* (histopathology)          1 (2.5)
   *Aspergillus* (histopathology)^b^             23 (56)
   Probable case (galactomannan positive)        2 (5)
  *Mucorales* (n = 37)                           
   *Rhizomucor* (culture or histopathology)^a^   2 (5)
   *Rhizopus* (culture)^b^                       8 (21)
   *Rhizopus microsporus*                        1 (3)
   *Rhizopus arrhizus*                           2 (5)
   *Mucorales* (histopathology)^b^               24 (63)

^a^Special immunostaining for *Rhizomucor.*

^b^Identification to the species level was not performed or reported.

### Treatment {#s11}

Treatment of invasive fungal carotiditis is reviewed in [Table 4](#T4){ref-type="table"}. Patients with IA received predominantly amphotericin-based (34%) or voriconazole-based (17%) regimens, though several (7%) received isavuconazole. Patients with IM primarily received amphotericin-based regimens (73%). Twenty-two patients overall (28%) did not receive antifungal therapy due to delayed diagnosis or poor prognosis. A majority of patients (65%) underwent surgical debridement. Other interventions included aneurysm coil embolization (n = 9), aneurysmal clipping (n = 2), carotid stenting (n = 2), and carotid bypass surgery (n = 2).

###### 

Treatment and Outcomes of Invasive Fungal Carotiditis

  Treatment and Outcomes           *Aspergillus* sp. (n = 41)   *Mucorales* (n = 37)   Total (n = 78)   *P*
  -------------------------------- ---------------------------- ---------------------- ---------------- ------
  Antifungal treatment, No. (%)                                                                         
   Amphotericin B                  14 (34)                      27 (73)                41 (53)          \-
   Voriconazole                    7 (17)                       0                      7 (9)            \-
   Isavuconazole                   3 (7)                        0                      3 (4)            \-
   Echinocandin                    2 (5)                        0                      2 (3)            \-
   Other antifungal                2 (5)                        1 (3)                  3 (4)            \-
   No treatment                    13 (32)                      9 (24)                 22 (28)          \-
  Adjunctive therapies, No. (%)                                                                         
   Hyperbaric oxygen               0                            6 (16)                 6 (8)            \-
  Surgical intervention, No. (%)                                                                        
   Surgical debridement            26 (63)                      25 (68)                51 (65)          .885
   Coil embolization               6 (15)                       3 (8)                  9 (12)           .590
   Aneurysm clipping               2 (5)                        0                      2 (3)            .546
   Carotid stent                   1 (2)                        1 (3)                  2 (3)            .942
   Carotid bypass                  2 (5)                        0                      2 (3)            .546
  Outcomes, No. (%)                                                                                     
   Carotid involvement                                                                                  
    Occlusion or thrombus          19 (46)                      31 (84)                50 (64)          .001
    Aneurysm or rupture            22 (54)                      6 (16)                 28 (36)          .001
   Complications                                                                                        
    Cerebral infarct               20 (49)                      19 (51)                39 (50)          .999
    Subarachnoid hemorrhage        17 (41)                      2 (5)                  19 (24)          .001
    Cavernous sinus thrombosis     3 (7)                        12 (32)                15 (19)          .012
    Mortality at 6 wk (42 d)       4 (10)                       17 (46)                21 (27)          .001
    Mortality at 12 wk (84 d)      10 (24)                      22 (59)                32 (41)          .003
    Mortality at 2 y (720 d)       31 (76)                      24 (65)                55 (71)          .429

### Outcomes {#s12}

Carotid complications identified in this review included occlusion, thrombosis, aneurysm formation, and rupture. Outcomes are represented in [Table 4](#T4){ref-type="table"}. In cases involving *Mucorales*, occlusion or thrombosis of the ICA was more frequent (84% vs 46%; *P* = .001) compared with IA. Patients with IA were more likely to develop SAH (41% vs 5%; *P* \< .001). Half of all patients experienced cerebral infarcts. All-cause mortality at 6 weeks, 12 weeks, and 2 years was 27%, 41%, and 71%, respectively. Mortality at 6 weeks was significantly higher for patients with invasive fungal carotiditis due to IM (46% vs 10%; *P* = .001), whereas mortality was similar for patients with IM and IA at 2 years (65% vs 76%; *P* = .429). Survival curves are presented in [Figure 2](#F2){ref-type="fig"}. Five patients who died quickly (4 with mucormycosis, 1 with aspergillosis) with no follow-up time specified were assigned a follow-up time of 7 days. The median time from symptom onset to death was 150 days for cases due to *Aspergillus* and 51 days for cases due to *Mucorales* species.

![Survival time from symptom onset of invasive fungal carotiditis due to *Aspergillus* and *Mucorales*.](ofz392f0002){#F2}

Discussion {#s13}
==========

IFD is an increasingly important cause of mortality among immunosuppressed patients \[[@CIT0015]\]. Invasive fungal carotiditis is a unique presentation of IFD that typically progresses by contiguous extension from sino-nasal, sino-orbital, or ototemporal locations to involve the carotid artery, with devastating consequences.

Major risk factors for IFD include HM, HCT, SOT, and DM. In this series, DM was a key risk factor for patients, serving as the most frequent individual primary risk factor for IFD. This was especially prevalent in cases of IM. Notably, among the cases of invasive fungal carotiditis identified, 19% of patients had no apparent risk factors for IFD. The reasons for this observation include prior bacterial or viral infections leading to disruption of the sino-nasal mucosa or ear canal epithelium, making those tissues susceptible to hyphal invasion \[[@CIT0027]\], or undiagnosed immunodeficiencies in otherwise healthy hosts \[[@CIT0028], [@CIT0029]\]. Nonetheless, these findings indicate that early recognition of at-risk patients may be problematic.

Cranial IFD is challenging to diagnose given the nonspecific nature of the symptoms and the overlap with many autoimmune and malignant diseases involving the paranasal sinuses, orbital apex, or skull base. Patients with invasive fungal carotiditis were frequently treated with systemic glucocorticoids for misdiagnosed inflammatory syndromes. For this reason, cranial IFD should be suspected in patients with worsening symptoms or imaging findings despite antibacterial or anti-inflammatory therapy. Determining a diagnosis through biopsy ought to be considered before administration of glucocorticoids in at-risk patients.

Yet even when suspicion is high and biopsy is pursued, barriers to diagnosis remain. Involved areas of the skull base may be technically difficult to access \[[@CIT0030], [@CIT0031]\]. In the reviewed cases, when surgical biopsy was obtained, negative results or inadequate sampling resulted in delayed diagnosis \[[@CIT0032]\]. Reinforcing these challenges, a significant group of patients (27%) were diagnosed only postmortem, suggesting that a diagnosis of invasive fungal carotiditis may be missed despite recent advances in imaging, surgery, and microbiologic testing. Novel diagnostic strategies such as polymerase chain reaction (PCR) assays should be considered to enhance diagnostic yield when suspicion for cranial IFD is high, especially with *Mucorales* species \[[@CIT0033]\].

Treatment of IFD involves both medical and surgical strategies \[[@CIT0034]\]. Voriconazole remains the firstline antifungal agent for the treatment of IA, though use of newer triazoles such as isavuconazole has begun to increase \[[@CIT0035], [@CIT0036]\], including among patients who are unable to receive voriconazole due to drug--drug interactions \[[@CIT0037]\]. A majority of patients with invasive fungal carotiditis received optimal antifungal therapy and surgical intervention, yet mortality remained high. Further investigation is essential to determine the optimal therapeutic strategies of cranial IFD with carotid involvement.

Vascular complications involving the intracranial blood vessels have not commonly been associated with IFD \[[@CIT0001], [@CIT0016], [@CIT0038]\]. Yet, 74 cases of invasive fungal carotiditis were identified in the literature, as well as 4 cases at our own institution since 2003. Half of those patients experienced associated strokes, and many others experienced SAH or CS thrombosis. Notably, even patients who appeared to improve clinically on antifungal therapy went on to develop vascular complications, raising the question of whether more aggressive vascular screening and intervention should be undertaken in patients with cranial IFD. We would recommend in patients with disease adjacent to the ICA, with or without visible narrowing of the ICA, or involving the cavernous sinus or petrous bone, that a magnetic resonance image/magnetic resonance angiogram (MRI/MRA) be performed \[[@CIT0039]\]. If the MRI/MRA reveals any vascular abnormalities, the risks and benefits of endovascular intervention should be discussed. In several cases reviewed, aggressive vascular interventions including coil embolization of aneurysms or carotid bypass have led to successful outcomes \[[@CIT0010], [@CIT0012], [@CIT0040]\].

Although IFD with carotid involvement has previously been described \[[@CIT0011], [@CIT0012], [@CIT0040]\], this study includes the largest number of patients to date and demonstrates the diverse spectrum of clinical syndromes that may lead to carotid involvement, as well as the varying manifestations of carotid complications, including occlusion, thrombosis, aneurysm formation, or rupture. Limitations of this study include the use of retrospective data, varying follow-up times, missing data, challenges in identifying anatomic sites of infection, and lack of clear definition between distinct manifestations of cranial IFD.

Invasive fungal carotiditis is a rare but distinct manifestation of cranial IFD. Given the nonspecific presentation, technically difficult microbiologic identification, and provider inexperience involving this syndrome, diagnosis is often delayed. Little is known about the optimal therapeutic approach to this disease, but multidisciplinary collaboration between otolaryngology, vascular, medicine, and infectious disease teams is critical. Early consideration of cranial IFD, an aggressive approach to biopsy and surgical debridement, determination of appropriate antifungal therapy, and routine vascular imaging and endovascular intervention should be considered to reduce the high mortality of this unique disease.

Supplementary Data {#s14}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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